CoChat

Targeted Brain Derived Neurotropic Factors (BDNF) Delivery across the Blood-Brain Barrier for Neuro-Protection Using Magnetic Nano Carriers: An In-Vitro Study

Open access
Pilakka-Kanthikeel, Sudheesh, Atluri, Venkata Subba Rao, Sagar, Vidya, Saxena, Shailendra K., Nair, Madhavan · 2013 · PLoS ONE
Cited by 135

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Parenteral use of drugs; such as opiates exert immunomodulatory effects and serve as a cofactor in the progression of HIV-1 infection, thereby potentiating HIV related neurotoxicity ultimately leading to progression of NeuroAIDS. Morphine exposure is known to induce apoptosis, down regulate cAMP response element-binding (CREB) expression and decrease in dendritic branching and spine density in cultured cells. Use of neuroprotective agent; brain derived neurotropic factor (BDNF), which protects neurons against these effects, could be of therapeutic benefit in the treatment of opiate addiction. Previous studies have shown that BDNF was not transported through the blood brain barrier (BBB) in-vivo.; and hence it is not effective in-vivo. Therefore development of a drug delivery system that can cross BBB may have significant therapeutic advantage. In the present study, we hypothesized that magnetically guided nanocarrier may provide a viable approach for targeting BDNF across the BBB. We developed a magnetic nanoparticle (MNP) based carrier bound to BDNF and evaluated its efficacy and ability to transmigrate across the BBB using an in-vitro BBB model. The end point determinations of BDNF that crossed BBB were apoptosis, CREB expression and dendritic spine density measurement. We found that transmigrated BDNF was effective in suppressing the morphine induced apoptosis, inducing CREB expression and restoring the spine density. Our results suggest that the developed nanocarrier will provide a potential therapeutic approach to treat opiate addiction, protect neurotoxicity and synaptic density degeneration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0062241

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 65

  1. CJ Guo, 2002, Morphine enhances HIV infection of human blood mononuclear phagocytes through modulation of beta-chemokines and CCR5 receptor, J Investig Med, 50, 435, 10.1136/jim-50-06-03 · DOI
  2. V Purohit, 2011, Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia, Mol Neurobiol, 44, 102, 10.1007/s12035-011-8195-z · DOI
  3. A Mansour, 1995, Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications, Trends Neurosci, 18, 22, 10.1016/0166-2236(95)93946-U · DOI · Paper page
  4. DR Wallace, 2006, HIV neurotoxicity: potential therapeutic interventions, J Biomed Biotechnol, 2006, 65741, 10.1155/JBB/2006/65741 · DOI
  5. MP Nair, 1997, Immunoregulatory effects of morphine on human lymphocytes, Clin Diagn Lab Immunol, 4, 127, 10.1128/CDLI.4.2.127-132.1997 · DOI
  6. D Yin, 1999, Fas-mediated cell death promoted by opioids, Nature, 397, 218, 10.1038/16612 · DOI · Paper page
  7. PC Singhal, 1998, Morphine enhances macrophage apoptosis, J Immunol, 160, 1886, 10.4049/jimmunol.160.4.1886 · DOI · Paper page
  8. SG Ayre, 1989, New approaches to the delivery of drugs to the brain, Med Hypotheses, 29, 283, 10.1016/0306-9877(89)90113-8 · doi:10.1016/0306-9877(89)90113-8
  9. AA Hurwitz, 1994, The role of the blood-brain barrier in HIV infection of the central nervous system, Adv Neuroimmunol, 4, 249, 10.1016/S0960-5428(06)80263-9 · DOI
  10. AL Betz, 1986, Specialized properties and solute transport in brain capillaries, Annu Rev Physiol, 48, 241, 10.1146/annurev.ph.48.030186.001325 · DOI · Paper page
  11. K Itoh, 2000, Neuronal damage of the substantia nigra in HIV-1 infected brains, Acta Neuropathol, 99, 376, 10.1007/s004010051139 · DOI
  12. GJ Wang, 2004, Decreased brain dopaminergic transporters in HIV-associated dementia patients, Brain, 127, 2452, 10.1093/brain/awh269 · DOI · Paper page
  13. RL Nosheny, 2007, Brain-derived neurotrophic factor prevents the nigrostriatal degeneration induced by human immunodeficiency virus-1 glycoprotein 120 in vivo, Eur J Neurosci, 25, 2275, 10.1111/j.1460-9568.2007.05506.x · DOI
  14. A Bachis, 2003, Brain-derived neurotrophic factor inhibits human immunodeficiency virus-1/gp120-mediated cerebellar granule cell death by preventing gp120 internalization, J Neurosci, 23, 5715, 10.1523/JNEUROSCI.23-13-05715.2003 · DOI
  15. I Mocchetti, 2007, Brain-derived neurotrophic factor prevents human immunodeficiency virus type 1 protein gp120 neurotoxicity in the rat nigrostriatal system, Ann N Y Acad Sci, 1122, 144, 10.1196/annals.1403.010 · DOI
  16. C Hyman, 1991, BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra, Nature, 350, 230, 10.1038/350230a0 · DOI · Paper page
  17. CA Altar, 1992, Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo, Proc Natl Acad Sci U S A, 89, 11347, 10.1073/pnas.89.23.11347 · DOI · Paper page
  18. LA Mamounas, 1995, Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain, J Neurosci, 15, 7929, 10.1523/JNEUROSCI.15-12-07929.1995 · DOI · Paper page
  19. BH Han, 2000, BDNF blocks caspase-3 activation in neonatal hypoxia-ischemia, Neurobiol Dis, 7, 38, 10.1006/nbdi.1999.0275 · DOI · Paper page
  20. WM Pardridge, 2007, Blood-brain barrier delivery, Drug Discov Today, 12, 54, 10.1016/j.drudis.2006.10.013 · DOI · Paper page
  21. WM Pardridge, 1998, Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration, Pharm Res, 15, 576, 10.1023/A:1011981927620 · DOI
  22. SS Suri, 2007, Nanotechnology-based drug delivery systems, J Occup Med Toxicol, 2, 16, 10.1186/1745-6673-2-16 · DOI · Paper page
  23. ZM Saiyed, 2007, Activity and stability of alkaline phosphatase (ALP) immobilized onto magnetic nanoparticles (Fe3O4), J Biotechnol, 131, 240, 10.1016/j.jbiotec.2007.06.017 · DOI
  24. ZM Saiyed, 2007, Extraction of DNA from agarose gel using magnetic nanoparticles (magnetite or Fe3O4), Anal Biochem, 363, 288, 10.1016/j.ab.2007.01.008 · doi:10.1016/j.ab.2007.01.008
  25. A Boyum, 1968, Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g, Scand J Clin Lab Invest, Suppl 97, 77
  26. N Gandhi, 2010, Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood-brain barrier dysfunction: implications for HIV-1-associated neurocognitive disorder, J Neurovirol, 16, 294, 10.3109/13550284.2010.499891 · DOI
  27. Y Persidsky, 1997, A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis, J Immunol, 158, 3499, 10.4049/jimmunol.158.7.3499 · DOI · Paper page
  28. SD Mahajan, 2005, Morphine modulates chemokine gene regulation in normal human astrocytes, Clin Immunol, 115, 323, 10.1016/j.clim.2005.02.004 · DOI
  29. Y Xia, 2010, Brain-derived neurotrophic factor prevents phencyclidine-induced apoptosis in developing brain by parallel activation of both the ERK and PI-3K/Akt pathways, Neuropharmacology, 58, 330, 10.1016/j.neuropharm.2009.10.009 · DOI · Paper page
  30. Y Li, 2007, Chronic morphine exposure alters the dendritic morphology of pyramidal neurons in visual cortex of rats, Neurosci Lett, 418, 227, 10.1016/j.neulet.2007.03.023 · DOI
  31. CA Chapleau, 2008, The actions of BDNF on dendritic spine density and morphology in organotypic slice cultures depend on the presence of serum in culture media, J Neurosci Methods, 169, 182, 10.1016/j.jneumeth.2007.12.006 · DOI
  32. S Roy, 1996, Effects of opioids on the immune system, Neurochem Res, 21, 1375, 10.1007/BF02532379 · DOI · Paper page
  33. GB Stefano, 1996, Opioid and opiate immunoregulatory processes, Crit Rev Immunol, 16, 109, 10.1615/CritRevImmunol.v16.i2.10 · DOI · Paper page
  34. SA Strathdee, 2010, Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions, Curr HIV/AIDS Rep, 7, 99, 10.1007/s11904-010-0043-7 · DOI · Paper page
  35. SR Alcala-Barraza, 2010, Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS, J Drug Target, 18, 179, 10.3109/10611860903318134 · DOI · Paper page
  36. HJ James, 1999, Expression of caspase-3 in brains from paediatric patients with HIV-1 encephalitis, Neuropathol Appl Neurobiol, 25, 380, 10.1046/j.1365-2990.1999.00195.x · doi:10.1046/j.1365-2990.1999.00195.x
  37. GA Garden, 2002, Caspase cascades in human immunodeficiency virus-associated neurodegeneration, J Neurosci, 22, 4015, 10.1523/JNEUROSCI.22-10-04015.2002 · DOI · Paper page
  38. 2001, Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations, Clin Pharmacokinet, 40, 907, 10.2165/00003088-200140120-00003 · DOI · Paper page
  39. AL Betz, 1978, Polarity of the blood-brain barrier: neutral amino acid transport into isolated brain capillaries, Science, 202, 225, 10.1126/science.211586 · DOI · Paper page
  40. AL Betz, 1980, Polarity of the blood-brain barrier: distribution of enzymes between the luminal and antiluminal membranes of brain capillary endothelial cells, Brain Res, 192, 17, 10.1016/0006-8993(80)91004-5 · DOI · Paper page
  41. RJ Mandel, 1999, Nerve growth factor expressed in the medial septum following in vivo gene delivery using a recombinant adeno-associated viral vector protects cholinergic neurons from fimbria-fornix lesion-induced degeneration, Exp Neurol, 155, 59, 10.1006/exnr.1998.6961 · DOI
  42. B Blits, 2003, Adeno-associated viral vector-mediated neurotrophin gene transfer in the injured adult rat spinal cord improves hind-limb function, Neuroscience, 118, 271, 10.1016/S0306-4522(02)00970-3 · DOI
  43. LR Williams, 1986, Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection, Proc Natl Acad Sci U S A, 83, 9231, 10.1073/pnas.83.23.9231 · DOI · Paper page
  44. GA Silva, 2007, Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier, Surg Neurol, 67, 113, 10.1016/j.surneu.2006.08.033 · DOI
  45. ZM Saiyed, 2010, Magnetic nanoformulation of azidothymidine 5′-triphosphate for targeted delivery across the blood-brain barrier, Int J Nanomedicine, 5, 157
  46. B Chertok, 2008, Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors, Biomaterials, 29, 487, 10.1016/j.biomaterials.2007.08.050 · DOI · Paper page
  47. A Ito, 2005, Medical application of functionalized magnetic nanoparticles, J Biosci Bioeng, 100, 1, 10.1263/jbb.100.1 · DOI · Paper page
  48. C Alexiou, 2006, Targeting cancer cells: magnetic nanoparticles as drug carriers, Eur Biophys J, 35, 446, 10.1007/s00249-006-0042-1 · DOI · Paper page
  49. AS Lubbe, 1996, Preclinical experiences with magnetic drug targeting: tolerance and efficacy, Cancer Res, 56, 4694
  50. SG Kwon, 2007, Kinetics of monodisperse iron oxide nanocrystal formation by “heating-up” process, J Am Chem Soc, 129, 12571, 10.1021/ja074633q · DOI · Paper page
  51. ZM Saiyed, 2009, AZT 5′-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells, J Neurovirol, 15, 343, 10.1080/13550280903062813 · DOI
  52. M Kaul, 2001, Pathways to neuronal injury and apoptosis in HIV-associated dementia, Nature, 410, 988, 10.1038/35073667 · DOI · Paper page
  53. R Goswami, 1998, Cyclic AMP protects against staurosporine and wortmannin-induced apoptosis and opioid-enhanced apoptosis in both embryonic and immortalized (F-11kappa7) neurons, J Neurochem, 70, 1376, 10.1046/j.1471-4159.1998.70041376.x · DOI
  54. PC Singhal, 1999, Morphine promotes apoptosis in Jurkat cells, J Leukoc Biol, 66, 650, 10.1002/jlb.66.4.650 · doi:10.1002/jlb.66.4.650
  55. DO Freier, 1993, Morphine-induced alterations in thymocyte subpopulations of B6C3F1 mice, J Pharmacol Exp Ther, 265, 81, 10.1016/S0022-3565(25)38147-4 · doi:10.1016/s0022-3565(25)38147-4
  56. BA Fuchs, 1993, Morphine induces apoptosis in murine thymocytes in vivo but not in vitro: involvement of both opiate and glucocorticoid receptors, J Pharmacol Exp Ther, 266, 417, 10.1016/S0022-3565(25)38348-5 · doi:10.1016/s0022-3565(25)38348-5
  57. R Bernabeu, 1997, Involvement of hippocampal cAMP/cAMP-dependent protein kinase signaling pathways in a late memory consolidation phase of aversively motivated learning in rats, Proc Natl Acad Sci U S A, 94, 7041, 10.1073/pnas.94.13.7041 · DOI · Paper page
  58. SM Taubenfeld, 1999, A molecular correlate of memory and amnesia in the hippocampus, Nat Neurosci, 2, 309, 10.1038/7217 · DOI
  59. M Cammarota, 2000, Learning-associated activation of nuclear MAPK, CREB and Elk-1, along with Fos production, in the rat hippocampus after a one-trial avoidance learning: abolition by NMDA receptor blockade, Brain Res Mol Brain Res, 76, 36, 10.1016/S0169-328X(99)00329-0 · DOI · Paper page
  60. H Viola, 2000, Phosphorylated cAMP response element-binding protein as a molecular marker of memory processing in rat hippocampus: effect of novelty, J Neurosci, 20, RC112, 10.1523/JNEUROSCI.20-23-j0002.2000 · DOI · Paper page
  61. M Alonso, 2005, Endogenous BDNF is required for long-term memory formation in the rat parietal cortex, Learn Mem, 12, 504, 10.1101/lm.27305 · DOI · Paper page
  62. F Sarti, 2007, Acute cocaine exposure alters spine density and long-term potentiation in the ventral tegmental area, Eur J Neurosci, 26, 749, 10.1111/j.1460-9568.2007.05689.x · DOI · Paper page
  63. M Frankfurt, 2011, Cocaine alters dendritic spine density in cortical and subcortical brain regions of the postpartum and virgin female rat, Synapse, 65, 955, 10.1002/syn.20918 · DOI · Paper page
  64. EJ Nestler, 2001, Molecular basis of long-term plasticity underlying addiction, Nat Rev Neurosci, 2, 119, 10.1038/35053570 · DOI · Paper page
  65. TE Robinson, 1999, Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine, Eur J Neurosci, 11, 1598, 10.1046/j.1460-9568.1999.00576.x · DOI · Paper page

Cited by

See all 135

Metadata

Authors
Pilakka-Kanthikeel, S., Atluri, V. S. R., Sagar, V., Saxena, S. K., & Nair, M.
Venue
PLoS ONE
Published
2013-04-30
Volume
8
Issue
4
Pages
e62241
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1966943736
Cited by
135
References
7
FWCI
5.15
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted Brain Derived Neurotropic Factors (BDNF) Delivery across the Blood-Brain Barrier for Neuro-Protection Using Magnetic Nano Carriers: An In-Vitro Study. https://app.cochat.ai/papers/10.1371/journal.pone.0062241
The paper
Pilakka-Kanthikeel, S., Atluri, V. S. R., Sagar, V., Saxena, S. K., & Nair, M. (2013). Targeted Brain Derived Neurotropic Factors (BDNF) Delivery across the Blood-Brain Barrier for Neuro-Protection Using Magnetic Nano Carriers: An In-Vitro Study. PLoS ONE. https://doi.org/10.1371/journal.pone.0062241

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.